EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Alvespimycin Inhibits Heat Shock Protein 90 and Overcomes Imatinib Resistance in Chronic Myeloid Leukemia Cell Lines

Raquel Alves iD, Diogo Santos, Joana Jorge iD, Ana Cristina Gonçalves iD, Steve Catarino iD, Henrique Girão iD, Joana Barbosa Melo iD, Ana Bela Sarmento-Ribeiro iD

Molecules · 2023

DOI: 10.3390/molecules28031210 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Molecules, 2023. Verfasst von Raquel Alves und 7 weiteren Autor:innen. Beteiligte Einrichtung: Laboratory of Oncobiology and Hematology (LOH), University Clinics of Hematology and Oncology, Group of Environmental Genetics of Oncobiology (CIMAGO…. Hauptthemen laut MEDLINE: Antineoplastic Agents, Leukemia, Myelogenous, Chronic, BCR-ABL Positive. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 42 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: CIMAGO - Center of Investigation on Environment, Genetics and Oncobiology, Fundação para a Ciência e Tecnologia, University of Coimbra, Portugal.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Heat shock protein 90 (HSP90) facilitates folding and stability and prevents the degradation of multiple client proteins. One of these HSP90 clients is BCR-ABL, the oncoprotein characteristic of chronic myeloid leukemia (CML) and the target of tyrosine kinase inhibitors, such as imatinib. Alvespimycin is an HSP90 inhibitor with better pharmacokinetic properties and fewer side effects than other similar drugs, but its role in overcoming imatinib resistance is not yet clarified. This work studied the therapeutic potential of alvespimycin in imatinib-sensitive (K562) and imatinib-resistant (K562-RC and K562-RD) CML cell lines. Metabolic activity was determined by the resazurin assay. Cell death, caspase activity, mitochondrial membrane potential, and cell cycle were evaluated by means of flow cytometry. Cell death was also analyzed by optical microscopy. HSPs expression levels were assessed by western blotting. Alvespimycin reduced metabolic activity in a time-, dose-, and cell line-dependent manner. Resistant cells were more sensitive to alvespimycin with an IC50 of 31 nM for K562-RC and 44 nM for K562-RD, compared to 50 nM for K562. This drug induced apoptosis via the mitochondrial pathway. In K562 cells, alvespimycin induced cell cycle arrest in G0/G1. As a marker of HSP90 inhibition, a significant increase in HSP70 expression was observed. Our results suggest that alvespimycin might be a new therapeutic approach to CML treatment, even in cases of resistance to imatinib.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antineoplastic AgentsLeukemia, Myelogenous, Chronic, BCR-ABL PositiveHumansApoptosisCell Line, TumorDrug Resistance, NeoplasmFusion Proteins, bcr-ablHeat-Shock ProteinsImatinib MesylateK562 CellsHSP90 Heat-Shock ProteinsBenzoquinonesLactams, Macrocyclic

Stichwörter der Autor:innen

chronic myeloid leukemiaheat shock proteinimatinib resistance

Substanzen

Antineoplastic AgentsFusion Proteins, bcr-ablHeat-Shock ProteinsImatinib MesylateHSP90 Heat-Shock Proteins17-(dimethylaminoethylamino)-17-demethoxygeldanamycinBenzoquinonesLactams, Macrocyclic

Autor:innen und Institutionen

  • Laboratory of Oncobiology and Hematology (LOH), University Clinics of Hematology and Oncology, Group of Environmental Genetics of Oncobiology (CIMAGO), Faculty of Medicine (FMUC), University of Coimbra, 3000-548 Coimbra…
  • Coimbra Institute for Clinical and Biomedical Research (iCBR), Faculty of Medicine (FMUC), University of Coimbra, 3000-548 Coimbra, Portugal.
  • Center for Innovative Biomedicine and Biotechnology (CIBB), 3004-531 Coimbra, Portugal.
  • Clinical Academic Center of Coimbra (CACC), 3000-370 Coimbra, Portugal.
  • Cytogenetics and Genomics Laboratory, Institute of Cellular and Molecular Biology, Faculty of Medicine (FMUC), 3000-548 Coimbra, Portugal.
  • Hematology Service, Centro Hospitalar Universitário de Coimbra (CHUC), 3004-561 Coimbra, Portugal.

ORCID-Profile: Raquel Alves, Joana Jorge, Ana Cristina Gonçalves, Steve Catarino, Henrique Girão, Joana Barbosa Melo, Ana Bela Sarmento-Ribeiro

Förderung

  • CIMAGO - Center of Investigation on Environment, Genetics and Oncobiology
  • Fundação para a Ciência e Tecnologia
  • University of Coimbra, Portugal
  • Foundation for Science and Technology (FCT)
  • COMPETE-FEDER
  • FCT

Zitieren

APA

Alves, R., Santos, D., Jorge, J., Gonçalves, A. C., Catarino, S., Girão, H., Melo, J. B., & Sarmento-Ribeiro, A. B. (2023). Alvespimycin Inhibits Heat Shock Protein 90 and Overcomes Imatinib Resistance in Chronic Myeloid Leukemia Cell Lines. Molecules. https://doi.org/10.3390/molecules28031210

Vancouver

Alves R, Santos D, Jorge J, Gonçalves AC, Catarino S, Girão H, et al. Alvespimycin Inhibits Heat Shock Protein 90 and Overcomes Imatinib Resistance in Chronic Myeloid Leukemia Cell Lines. Molecules. 2023. doi:10.3390/molecules28031210

BibTeX
@article{Alves2023,
  author = {Alves, Raquel and Santos, Diogo and Jorge, Joana and Gonçalves, Ana Cristina and Catarino, Steve and Girão, Henrique and Melo, Joana Barbosa and Sarmento-Ribeiro, Ana Bela},
  title = {Alvespimycin Inhibits Heat Shock Protein 90 and Overcomes Imatinib Resistance in Chronic Myeloid Leukemia Cell Lines},
  journal = {Molecules},
  year = {2023},
  doi = {10.3390/molecules28031210}
}
Kostenlos starten →